Jill M. Broadfoot
Net Worth
Last updated:
What is Jill M. Broadfoot net worth?
The estimated net worth of Ms. Jill M. Broadfoot is at least $3,619,153 as of 31 May 2024. She has earned $6,383 from insider trading and has received compensation worth at least $3,612,770 in aTyr Pharma, Inc..
What is the salary of Jill M. Broadfoot?
Ms. Jill M. Broadfoot salary is $516,110 per year as Chief Financial Officer in aTyr Pharma, Inc..
How old is Jill M. Broadfoot?
Ms. Jill M. Broadfoot is 63 years old, born in 1962.
What stocks does Jill M. Broadfoot currently own?
As insider, Ms. Jill M. Broadfoot owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| aTyr Pharma, Inc. (LIFE) | Chief Financial Officer | 27,960 | $0 | $0 |
What does aTyr Pharma, Inc. do?
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Jill M. Broadfoot insider trading
aTyr Pharma, Inc.
Ms. Jill M. Broadfoot has made 4 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently she purchased 5,000 units of LIFE stock worth $8,950 on 31 May 2024.
The largest trade she's ever made was exercising 38,000 units of LIFE stock on 20 Sep 2018. As of 31 May 2024 she still owns at least 27,960 units of LIFE stock.
aTyr Pharma key executives
aTyr Pharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Sanjay S. Shukla (53) Pres, Chief Executive Officer & Director
- Ms. Jill M. Broadfoot (63) Chief Financial Officer
- Ms. Nancy E. Denyes Krueger (57) Gen. Counsel & Corporation Sec.